Takeaways The Canadian NOC formally moves Scenesse from special‑access cases to on‑label, publicly or privately reimbursed treatment for erythropoietic protoporphyria, e...
Takeaways The Teva Canada–Samsung Bioepis deal makes Opuviz (aflibercept biosimilar to Eylea) a commercially available, lower‑cost alternative in Canada’s wet AMD, DME, and retinal vein occlusio...
Takeaways Sobi’s Empaveli is now positioned to move from import‑only, limited‑access status into publicly funded, pan‑Canadian treatment for C3 glomerulopathy and primary IC‑MPGN, one ...
Takeaways: Lilly now offers Canadian pediatric endocrinologists a once‑weekly injectable that addresses both glycemic control and weight – two core drivers of aggressiv...
Takeaways: The Canadian approval of Besremi gives PharmaEssentia a new, targeted therapy in the chronic myeloproliferative neoplasm space, expanding its hematology/oncology footprint beyond Taiw...
Takeaways: This approval expands Padcev from later-line urothelial cancer into earlier-stage muscle-invasive bladder cancer, which should broaden Pfizer’s addressable market in Canada and streng...
Shots: Takeaways: Sevmia’s approval makes Apotex the first Canadian generic challenger in Wegovy, which should increase price competition, widen access to semaglutide for ch...
Takeaways: Vimkunya’s Health Canada approval turns Bavarian Nordic’s chikungunya shot into a genuinely global travel-vaccine franchise, which should drive uptake in Canadian travel cl...
Takeaways: Boey gives Allergan Aesthetics a differentiated entry point in Canadian aesthetics: a fast-onset, short-duration botulinum option that can attract first-time or co...
Takeaways: This approval strengthens Lilly’s competitive stance against other GLP-1/GIP agents in the obesity space by adding a disease-specific indication (OSA) that ties directl...
